An observational study in Atrial Fibrillation, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-21.
Sponsored by Peking University Third Hospital · Observational
In this study, the continuous inclusion of atrial fibrillation patients treated by catheter ablation in the Department of Cardiology, Peking University Third Hospital, through the collection of clinical data and outpatient follow-up, to explore the risk factors of atrial fibrillation recurrence after catheter ablation and the influencing factors of major clinical events in atrial fibrillation patients, and further guide the management mode of atrial fibrillation patients.
3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.
This study's planned enrollment of 300 is close to the median of 300 across 1,363 observational studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →Peking University Third Hospital is the lead sponsor of 735 studies on the registry; 262 are open to participants now.
Counted across the registry records on this site, refreshed daily.
In this study, atrial fibrillation patients who meet the inclusion criteria and those who do not meet the exclusion criteria were admitted to the Department of Cardiology of Peking University Third Hospital after catheter ablation from December 31, 2022 to December 31, 2023
Exclusion Criteria:
After radiofrequency ablation of patients with atrial fibrillation
Other: After radiofrequency ablation of atrial fibrillation
This study imposed an intervention. Clinical data were obtained by telephone or outpatient follow-up.
Compound cardiovascular event
Stroke, hemorrhage, re-hospitalization for atrial fibrillation and heart failure, and all-cause death
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University Third Hospital